Piloting a scale-up platform for high-quality human T-cells production.

Area of Science:

• Immunotherapy
• Cellular Therapy
• Oncology

Background:

• Adoptive cell therapy (ACT) is a promising cancer treatment, with CAR-T products driving market growth.
• Standardizing ACT manufacturing is crucial for accessibility and reproducibility.
• Understanding T-cell culture conditions is vital for effective expansion and differentiation.

Purpose of the Study:

• To evaluate adoptive T-cell culture platforms for large-scale production.
• To identify optimal conditions for high-quality cellular output with minimal cell death.
• To address scalability and reproducibility challenges in ACT manufacturing.

Main Methods:

• Assessed various adoptive T-cell culture platforms.
• Examined bioreactor parameters, media, supplements, and stimulation.
• Focused on achieving large-scale production (billions of cells) and high-quality output.

Main Results:

• Identified critical factors influencing T-cell expansion and differentiation.
• Demonstrated the potential for large-scale, reproducible T-cell manufacturing.
• Achieved high-quality cellular output with minimal cell death across evaluated platforms.

Conclusions:

• Optimized cell culture conditions are essential for robust ACT manufacturing.
• Scalable and reproducible ACT production is achievable.
• This research supports the advancement of ACT as a practical cancer therapeutic.